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Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is recommended for patients with high-risk
acute myeloid leukemia (AML). In many situations, a matched related (MRD) or matched unrelated donor
(MUD) is lacking, in which case unrelated cord blood units (UCB) provide an alternative. We analyzed the
outcome of consecutive high-risk AML patients prepared with reduced-intensity conditioning (RIC) regimens
and allografted with UCB (n ¼ 32) and compared their outcome with high-risk AML patients who underwent
transplantation with MRD/MUD (n ¼ 49) in the same period of time. Grade III to IV acute graft-versus-host
disease (GVHD) occurred slightly more frequently in the UCB group (25%) than in the MRD/MUD group (8%)
(P ¼ .069). Conversely, we found a lower incidence of extensive chronic GVHD in the UCB group (6%) than in
the MRD/MUD group (20%, P ¼ .085). Nonrelapse mortality at 4 years was 16% and 22% in the UCB and MRD/
MUD groups, respectively (P ¼ .529). The cumulative incidence of relapse at 4 years was signiﬁcantly higher in
the UCB group (60%) than in the MRD/MUD group (27%, P ¼ .006). Leukemia-free survival (LFS) and overall
survival (OS) at 4 years were 25% and 34%, respectively, in the UCB group and 50% and 56%, respectively, in the
MRD/MUD group (LFS, P ¼ .029; OS, P ¼ .072). Multivariate analyses adjusted by cytogenetics and disease
status at the time of Allo-HSCT revealed that use of UCB remained an independent predictive factor of shorter
LFS (hazard ratio, 2.0; 95% conﬁdence interval, 1.1 to 3.6; P ¼ .018), and was associated with a trend for shorter
OS (hazard ratio, 1.7; 95% conﬁdence interval, .9 to 3.2; P ¼ .093). Whereas UCB provides an alternative for
patients with high-risk AML lacking an MRD/MUD, the high incidence of relapse after RIC-based UCB Allo-
HSCT is a concern. Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as
the evaluation of other alternative donors in this context.
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Allogeneic hematopoietic stem cell transplantation (Allo-
HSCT) is the main curative treatment for patients with
nonfavorable acute myeloid leukemia (AML); however,
donor availability is a limitation for the process, and whenedgments on page 1564.
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14.06.006possible, transplantation from HLA-matched related donors
(MRD) is preferred. Transplantation from a 10/10
HLAematched unrelated donor (MUD) is another valuable
option, with an acceptable safety proﬁle, and compares
favorably with MRD [1-4]. In the absence of MRD or MUD,
use of umbilical cord blood (UCB) as an alternative donor has
emerged as a promising strategy. Indeed, because of a
permissive HLA disparity [5], the outcome of UCB Allo-HSCT
has been described to be similar to the results of unrelated
marrow transplantation in adults; thus, adding to the initialTransplantation.
Table 1
Patients’ Characteristics
Characteristic MRD/MUD (n ¼ 49) UCB (n ¼ 32) P Value
n % n %
Age, median (range), yr 54 (20-69) 50 (18-66) .032
Cytogenetics
Favorable 5 10 3 9
Intermediate 26 53 17 53 .992
Unfavorable 18 37 12 38
Disease status at Allo-HSCT
CR1 29 59 15 47
CR > 1 13 27 13 41 .547
No CR 7 14 4 13
Induction therapy for CR1
1 Course 8 28 5 33 .737
2 Courses 21 72 10 67
Conditioning regimen Flu þ Bu þ ATG Flu þ Cy þ TBI
GVHD prophylaxis CSA alone CSA þ MMF
Stem cell source PBSC UCB
Follow-up, median (range), mo 55 (28-100) 66 (30-87) .349
Flu indicates ﬂudarabine; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; CSA, cyclosporine A; MMF, mycophenolate mofetil; PBSC, peripheral
blood stem cells.
Data presented are n (%), unless otherwise indicated.
R. Devillier et al. / Biol Blood Marrow Transplant 20 (2014) 1560e1565 1561observation in children [6,7]. However, UCB Allo-HSCT in
adult recipients after myeloablative regimens is associated
with a graft failure rate of 8% [8] to 20% [7], slow hemato-
logical recovery, delayed immune reconstitution [9,10], high
risk of viral complication [11,12], and, thus, it unfavorably
compares with MRD [6,13]. More recently, the use of double
UCB units and reduced-intensity conditioning (RIC) regimens
reportedly supported rapid neutrophil recovery, low non-
relapse mortality (NRM), and produced similar outcomes
with other graft sources [14-16]. Consequently, UCB Allo-SCT
is increasingly considered as an option for high-risk AML
patients who lack an MRD/MUD in a risk-adapted strategy
[17,18]. Previously published studies that compared UCBwith
MRD or MUD [13,19-22] did not speciﬁcally focus on high-
risk AML. Here, we investigated the outcome of high-risk
AML patients undergoing RIC Allo-SCT from either MRD/
MUD or UCB at a single transplantation program.
PATIENTS AND METHODS
Selection Criteria
Patients with high-risk AML who had undergone Allo-HSCT after RIC
regimens were included in the present study. High risk was deﬁned ac-
cording to institutional guidelines, by the presence of at least 1 of the
following criteria: (1) absence of complete remission (CR) at the time of
Allo-SCT; (2) patient in second CR or more advanced CR (CR > 1), whatever
the initial cytogenetic outcome; (3) adverse karyotype abnormalities based
on the Medical Reseach Council cytogenetic stratiﬁcation [23]; or (4) ﬁrst CR
achieved after more than 1 induction course [24]. In this report, we
compared the outcome of selected patients who underwent transplantation
using MRD or MUD (MRD/MUD) and those using UCB when such a donor
was missing. Our institutional review board approved this study and all the
patients gave signed informed consent in accordance with the Helsinki
declaration.
UCB Group
All these patients underwent transplantation between 2005 and 2011.
The UCB group received a RIC regimen containing cyclophosphamide
(50 mg/kg/day during 1 day), ﬂudarabine (Fludara [Schering AG, Lys-Les-
Lannoy, France], 40 mg/m2/day for 5 days), and 2 Gy total body irradiation
[14]. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclo-
sporine A (started at day 3) and mycophenolate mofetil (from day 3 to
day þ30). No antithymocyte globulin (ATG) was given to the UCB patients.
All patients received granulocyte colonyestimulating factor from day þ1 to
hematological recovery. Selection criteria for cord blood units were as fol-
lows: (1) a maximum of 2 mismatches were allowed on the A, B, and DR loci
between the unit(s) and the recipient; (2) in patients receiving 2 units, a
maximum of 2 mismatches were allowed between both cord units; and (3)minimal dose of total nucleated cells by kilogram of body weight (TNC/kg) to
select the cord units was a total of 3.07 TNC/kg, with at least 1 unit with a
minimal dose of 2.07 TNC/kg in case of double cord transplantation.
MRD/MUD Group
The MRD/MUD group was used as a control group. We selected all pa-
tients who underwent transplantation for high-risk AML usingMRD orMUD
in the same period of time, and who received a RIC regimen based on
ﬂudarabine (Fludara [Schering AG, Lys-Les-Lannoy, France], 30 mg/m2/day
for 5 days), intravenous busulfan (Busilvex [Pierre Fabre, Boulogne-Bill-
ancourt, France], 3.2 mg/kg/d during 2 days) and rabbit ATG (Thymoglo-
buline [Genzyme, St. Germain-en-Laye, France], 2.5 or 5 mg/kg total dose)
because it represents our standard RIC regimen for Allo-HSCT using MRD or
MUD [25,26]. GVHD prophylaxis consisted of cyclosporine A alone started at
day 3. All patients were given peripheral blood stem cells as the graft
source from either an MRD or a high-level HLA MUD (on A, B, C, DR, and
DQ loci).
Endpoints and Statistical Analyses
Baseline characteristics of both MRD/MUD and UCB groups were
compared using the chi-square or Fisher’s test. MRD/MUD and UCB groups
were compared for the following endpoints: incidence of acute GVHD and
chronic GVHD [27,28], NRM rate, relapse, leukemia-free survival (LFS), and
overall survival (OS). Time to events was calculated from the date of Allo-
HSCT. Cumulative incidence of GVHD, NRM, and relapse were calculated
using the Prentice estimate, allowing for the consideration of competing
events [29,30]. The Kaplan-Meier method was used for OS and LFS analyses
[31]. For univariate analyses, Gray test and log-rank test were used to
identify factors inﬂuencing cumulative incidence and survival, respectively.
Variables that tend to be signiﬁcant (P < .10) in univariate analyses were
included in multivariate analyses. All survival analyses were computed with
the R 2.13.1 statistical software (http://www.R-project.org).
RESULTS
Patient and Transplantation Characteristics
Eighty-one consecutive patients met the selection criteria
and were included for analysis. MRD (n ¼ 36) and MUD
(n ¼ 13) were used for 49 patients (MRD/MUD group),
whereas 32 patients underwent transplantation with UCB.
The baseline patient characteristics are described in Table 1
and indicate no signiﬁcant difference between MRD/MUD
and UCB groups, except for age; UCB patients were younger.
In the UCB group, 9 (28%) and 23 (72%) patients received
single and double units, respectively. In the patients
receiving double cord units, HLA matching was 4/6 þ 4/6
(n ¼ 18), 5/6 þ 5/6 (n ¼ 3), 4/6 þ 5/6 (n ¼ 1), and 6/6 þ 6/6
(n ¼ 1). In the patients receiving single cord blood trans-
plantation, HLA matching was 4/6 (n ¼ 5), 5/6 (n ¼ 3), and
Table 2
Outcome after Allo-HSCT according to Donor Group
Outcome MRD/MUD (n ¼ 49)
% (95% CI)




Grade II-IV 18 (7-29) 41 (23-58) .041
Grade III-IV 8 (1-16) 25 (10-40) .069
Chronic GVHD
Overall 35 (21-48) 25 (10-40) .270
Extensive 20 (9-32) 6 (0-15) .085
Nonrelapse mortality 22 (11-34) 16 (3-28) .529
Relapse incidence 27 (14-40) 60 (42-78) .006
Leukemia-free survival 50 (38-67) 25 (13-45) .029
Overall survival 56 (43-72) 34 (21-65) .072
CI indicates conﬁdence interval.
All estimations are given at 48 months, except acute GVHD (day 100).
Figure 1. Cumulative incidences of NRM (A) and relapse (B) in the MRD/MUD
and UCB groups.
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TNC/kg (range, 3.2 to 8.0).
Transplantation-related Events
Four patients (12%) experienced graft failure in the UCB
group (single unit transplantation, n ¼ 2), whereas all pa-
tients who underwent transplantation from an MRD or MUD
engrafted. There was a trend for more grade III to IV acute
GVHD (25% versus 8%, P ¼ .069) and less extensive chronic
GVHD (5% versus 20%, P¼ .085) in UCB patients than inMRD/
MUD patients (Table 2). Sixteen patients (5 in the UCB group
and 11 in the MRD/MUD group) died without evidence of
relapse (Table 3). The cumulative incidence of NRM at 4 years
was 16% versus 22% (P ¼ .529) (Figure 1A) in the UCB and
MRD/MUD groups, respectively, whereas that of GVHD and
NRM were similar in patients receiving single versus double
UCB (data not shown).
Cumulative Incidence of Relapse
Relapse occurred in 19 UCB patients and in 14 MRD/MUD
patients, leading to a higher cumulative incidence of relapse
at 4 years of 60% versus 27% in UCB and MRD/MUD patients,
respectively (P ¼ .006) (Table 2, Figure 1B). We did not ﬁnd a
difference between patients who received single versus
double UCB (data not shown). Among patients who under-
went transplantation in CR1, the 4-year relapse incidence
remained signiﬁcantly higher in the UCB group than in the
MRD/MUD group (67% versus 24%, P ¼ .007).
Survival
We observed a lower 4-year LFS in the UCB group (25%)
than in the MRD/MUD group (50%) (P ¼ .029) (Table 2,
Figure 2A). There was a trend to a lower 4-year OS in UCB
patients (34%), but it was not signiﬁcantly different from that
in MRD/MUD patients (56%) (P ¼ .072) (Table 2, Figure 2B).
After adjustment in a multivariate model, including disease
status at the time of Allo-HSCT and cytogenetics, the use of
UCB signiﬁcantly inﬂuenced LFS (hazard ratio, 2.0; 95%Table 3
Causes of Death in Patients Who Died at Last Follow-Up (n ¼ 42)
Cause of Death MRD/MUD (n ¼ 21) UCB (n ¼ 21)
Deaths without evidence
of relapse
11 (52) 5 (24)
GVHD-related deaths 5 (24) 3 (14)
Infection without GVHD 5 (24) 2 (10)
Other 1 (5) 0 (0)
Relapse-related deaths 10 (48) 16 (76)
Data presented are n (%).conﬁdence interval, 1.1 to 3.6; P ¼ .018), and was associated
with a trend for shorter OS (hazard ratio, 1.7; 95% conﬁdence
interval, .9 to 3.2; P ¼ .093).
DISCUSSION
We analyzed high-risk AML patients who underwent
transplantation with UCB at a single institution and
compared their outcome with patients who underwent
transplantation with an MRD/MUD. To have a homoge-
neously treated control arm, we selected consecutive pa-
tients with high-risk AML who underwent transplantation
from an MRD/MUD in the same period of time and who
received a ﬂudarabine-busulfan-ATGebased RIC regimen
because it represented the standard of RIC at our institution
[25]. The incidence of grade III and IV acute GVHDwas higher
in the UCB group (25% versus 8%), who did not receive ATG,
whereas the entire MRD/MUD group did. On the contrary,
incidence of extensive chronic GVHD (6%) was 3-fold lower
in UCB than in MRD/MUD (20%). However, these differences
of GVHD incidence could be related to both graft source and
conditioning regimen, including GVHD prophylaxis disparity.
Our results that present a similar NRM of about 15% to 20%
in both UCB and MRD/MUD recipients suggest that RIC
Figure 2. Leukemia-free (A) and overall survival (B) in MRD/MUD and UCB
groups.
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patients who lack an MRD or MUD, without increased
transplantation-associated mortality. These results are in
line with previous reports on UCB RIC Allo-HSCT [14,16,32].
Several studies have compared the efﬁcacy of UCB Allo-
HSCT and have demonstrated that the incidence of relapseTable 4
Major Series of UCB Allo-HSCT Prepared with RIC or MAC and Including High Prop
Series N* Conditioning regimen % AML Acute GV
(III-IV)
RIC series
Present study 32 FLU-CY-TBI 2 Gy 100% 25%
Brunstein et al. [32] 121 FLU-CY-TBI 2 Gy þ/ ATG 82% 17%
Majhail et al. [33] 60 FLU-CY-TBI 2 Gy þ/ ATG 73% 26%
Oran et al. [37] 70 FLU-CY-TBI 2 Gy þ/ ATG 100% 16%
Ponce et al. [38] 30 FLU-CY-TT-TBI 4 Gy 71% 7%
MAC series
Atsuta et al. [35] 173 Different MAC 100% NA
Oran et al. [37] 45 FLU-CY-TBI 13 Gy 100% 31%
Sanz et al. [36] 49 TT-BU-Cy-ATG
TT-BU-FLU-ATG
100% 15%
Ooi et al. [42] 77 CY-AraC-FLU-TBI 12 Gy 100% 25%
NA indicates not available; TT, thiotepa; AraC, cytarabine.
* Number of patients who underwent transplantation from UCB in the series.is similar to MRD or MUD Allo-HSCT in different contexts of
hematological diseases and/or conditioning the regimen
intensity [13,22,32,33]. However, none of these studies spe-
ciﬁcally focused on high-risk AML patients who underwent
transplantation after RIC regimens; in this study, we specif-
ically evaluated the efﬁcacy of UCB compared with MRD/
MUD in patients with high-risk AML who underwent trans-
plantation after RIC. We observed a high incidence of relapse
after UCB Allo-HSCT (60%), whereas relapse occurred in 27%
of MRD/MUD patients, and this observation also stands true
in patients who underwent transplantation in CR1. Thus,
approximately one half of the patients who underwent
transplantation in this situation will relapse after UCB Allo-
SCT prepared with a nonmyeloablative regimen, showing
the insufﬁcient disease control of this procedure. We sup-
pose that the lower myeloablative potential of the condi-
tioning regimen used in the UCB group explains, in part, the
lower disease control. Indeed, we previously reported that in
unselected patients who underwent transplantation from an
MRD, the busulfan-based RIC resulted in better disease
control than the ﬂudarabine TBI-based nonmyeloablative
conditioning regimen [34]. However, this statement should
be conﬁrmed in the setting of UCB Allo-HSCT. To better assess
this issue, we reviewed a published series of UCB Allo-HSCT,
including a high proportion of patients with AML who
received either RIC or myeloablative conditioning (MAC)
regimens (Table 4). This review conﬁrms the high incidence
of relapse, approximately 50%, in patients who underwent
transplantation with UCB after a RIC regimen. Interestingly,
MAC regimens seem to produce better disease control, with
relapse rates ranging from 9% to 31%. However, Atsuta et al.
and Sanz et al. observed a high NRM of 33% and 39%,
respectively, offsetting the beneﬁt associated with better
disease control and eventually producing similar LFS (about
35%) when compared with the RIC regimen [35,36]. Oran
et al. directly compared the RIC and MAC regimens in UCB
Allo-HSCT for AML patients and showed a higher incidence
of relapse after RIC (43% versus 9%), leading to worse LFS
(31% versus 55%) [37]. These results stress how important it
is to measure and optimize the conditioning intensity in
various settings, deﬁned by the nature and stage of the un-
derlying disease for which Allo-HSCT is being used and by
the stem cell source. In the context of UCB Allo-HSCT for
high-risk AML patients, the optimal balance between trans-
plantation mortality and the antileukemic effect remains to
be deﬁned. A preparative regimen with increased/interme-
diate myeloablative potential but acceptable toxicity






25% 16% at 4 yr 60% at 4 yr 25% at 4 yr 34% at 4 yr
34% 19% at 2 yr 49% at 2 yr 31% at 2 yr 37% at 2 yr
33% 25% at 2 yr 47% at 2 yr 22% at 3 yr 31% at 3 yr
30% 19% at 2 yr 43% at 3 yr 31% at 3 yr NA
10% 28% at 2 yr 11% at 2 yr 60% at 2 yr 60% at 2 yr
28% 33% at 2 yr 31% at 2 yr 36% at 2 yr 43% at 2 yr
34% 27% at 2 yr 9% at 3 yr 55% at 3 yr NA
46% 39% at 2 yr 19% at 2 yr 37% at 4 yr NA
84% 10% at 5 yr 26% at 5 yr 63% at 5 yr NA
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[38]. Alternatively, Allo-HSCT from haploidentical donors
could be an interesting option. It was reported that outcomes
after T cellereplete haploidentical Allo-HSCT with post-
transplantation cyclophosphamide could approach those
after UCB or HLA matched related or unrelated donors
[39,40]. However, with no prospective comparison in the
speciﬁc setting of AML, the question of the best alternative
donor remains unsolved [41].
We conclude that although the use of UBC Allo-HSCT of-
fers a therapeutic option for high-risk AML patients without
an MRD or MUD, approximately one half will relapse and
have a poor outcome after receiving the RIC regimen. New
strategies to improve the antileukemic effect after UCB Allo-
SCT are needed, including the design and evaluation of
modiﬁed and improved myeloablative regimens with low
mortality, as well as post-transplantation therapies. Alter-
natively, other types of donors, including mismatched
unrelated or haploidentical donors, need consideration.ACKNOWLEDGMENTS
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